Archshiny Biotechnology Company Limited
Update：2024/12/24
Industries
Main Industry
Consumer Goods
Main Product/Service
Development of AI Software for Medical Imaging
Using our proprietary AI technology, we perform automatic segmentation of various types of brain tumors (such as acoustic neuroma, meningioma, and brain metastasis) on preoperative MRI scans, providing objective and accurate volumetric analysis of the tumors.
Development of AI Software for Medical Imaging
Read More
AI Detection Product Development.jpg
AI Detection Product Development
DeepBT? not only allows viewing DICOM images and inspecting AI results but also offers exceptional scalability to optimize existing workflows for physicians and create additional value. This includes value-added applications such as providing screening prioritization, proactive critical notifications, mobile and remote services, and customized services. These features not only offer more value-added services to medical institutions but also open up broader development opportunities for the application of deep learning technology, further integrating it closely with clinical workflows.
AI Detection Product Development
Read More
Medical Device Regulations and Certification Services.jpg
Medical Device Regulations and Certification Services
Using our proprietary AI technology, we perform automatic segmentation of various types of brain tumors (such as acoustic neuroma, meningioma, and brain metastasis) on preoperative MRI scans, providing objective and accurate volumetric analysis of the tumors.
Development of AI Software for Medical Imaging
Read More
AI Detection Product Development.jpg
AI Detection Product Development
DeepBT? not only allows viewing DICOM images and inspecting AI results but also offers exceptional scalability to optimize existing workflows for physicians and create additional value. This includes value-added applications such as providing screening prioritization, proactive critical notifications, mobile and remote services, and customized services. These features not only offer more value-added services to medical institutions but also open up broader development opportunities for the application of deep learning technology, further integrating it closely with clinical workflows.
AI Detection Product Development
Read More
Medical Device Regulations and Certification Services.jpg
Medical Device Regulations and Certification Services
Founded Year
2018
Unified Business No.
42997421
Status
Active
Number of Employees
1
Total Paid-in
Capital
15,700,000 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE."
Exclusive content for members
Members-only content. Please log in to access.
Introduction
AItewan BioMedical Technology Inc. was founded by Distinguished Professor Wu Yu-Te of National Yang Ming Chiao Tung University (NYCU), following the execution of two National Science and Technology Council (NSTC) Taiwan Germination Program I and II. These projects focused on the use of artificial intelligence to assist in the automatic annotation of brain tumor MRI images at multiple time points both pre- and post-operation, and on the development of the DeepBT intelligent precision medicine system for brain tumors: lesion detection and annotation over time (Tracker). The company was established with the approval of NYCU's spin-off regulations for AI-based smart healthcare startups, co-founded by Distinguished Professor Wu Yu-Te and Dr. Guo Wan-Yuo.
The brain tumor detection assistance system resulting from these NSTC research projects, known as the DeepBT Detector, has been exclusively licensed to NYCU and Taipei Veterans General Hospital. The DeepBT Detector has received multiple professional awards, including the "2022 Future Tech Award," the "19th National Innovation Award - Academic Research and Innovation Award," and the "National Innovation Advancement Award."
Our company's business philosophy emphasizes the full utilization of AI technology to enhance patient care quality, reduce the workload of physicians, and achieve the goals of fast, objective, quantitative, accurate, and seamless healthcare.
AItewan BioMedical Technology will continue to collaborate with medical institutions such as NYCU, Taipei Veterans General Hospital, Taichung Veterans General Hospital, Cheng Hsin General Hospital, Shin Kong Wu Huo-Shih Memorial Hospital, and the NYCU Affiliated Hospital. Additionally, the company will form strategic alliances with various information system vendors to assist in promoting and implementing AI technology.
The brain tumor detection assistance system resulting from these NSTC research projects, known as the DeepBT Detector, has been exclusively licensed to NYCU and Taipei Veterans General Hospital. The DeepBT Detector has received multiple professional awards, including the "2022 Future Tech Award," the "19th National Innovation Award - Academic Research and Innovation Award," and the "National Innovation Advancement Award."
Our company's business philosophy emphasizes the full utilization of AI technology to enhance patient care quality, reduce the workload of physicians, and achieve the goals of fast, objective, quantitative, accurate, and seamless healthcare.
AItewan BioMedical Technology will continue to collaborate with medical institutions such as NYCU, Taipei Veterans General Hospital, Taichung Veterans General Hospital, Cheng Hsin General Hospital, Shin Kong Wu Huo-Shih Memorial Hospital, and the NYCU Affiliated Hospital. Additionally, the company will form strategic alliances with various information system vendors to assist in promoting and implementing AI technology.
